Legislation Search

S. 3697: Support And Value Expectant Moms and Babies Act of 2026

This bill, known as the Support And Value Expectant Moms and Babies Act of 2026 (SAVE Moms and Babies Act of 2026), proposes several changes to how abortion drugs are regulated in the United States. The bill seeks to amend the Federal Food, Drug, and Cosmetic Act with the following key provisions:

Prohibitions on Abortion Drugs

The bill establishes a broad prohibition against the approval of new abortion drugs by the Secretary of Health and Human Services, including:

No new applications can be submitted for marketing any abortion drug.
No investigational use exemptions can be granted for abortion drugs.

Regulations on Previously Approved Abortion Drugs

For abortion drugs that are already approved as of the bill's enactment, the following conditions would apply:

No changes to their approved labeling that would allow their use after 70 days of gestation.
These drugs must only be dispensed through in-person administration by a health care practitioner and not through pharmacies.
Healthcare practitioners must be certified to prescribe these drugs, demonstrating abilities such as assessing pregnancy duration and diagnosing ectopic pregnancies.
Patients must receive documentation regarding the risks associated with the drug, and the practitioner must confirm the patient received this information.
All known adverse events related to these abortion drugs must be reported to the Food and Drug Administration (FDA).
The use of these drugs must be reported under state law, or similarly to surgical abortions in the absence of state law.

Reporting Requirements

The bill mandates that all health care practitioners, not just those prescribing abortion drugs, report any adverse events experienced by their patients associated with the use of these drugs to the FDA without revealing identifiable patient information.

Impact on Investigational Use

Any investigational use exemptions granted prior to the enactment of this bill will be deemed rescinded three years after the bill's enactment if they would not be granted under the new rules.

Definitions

Key terms are defined within the bill, including:

Abortion drug: Any drug intended to kill an unborn child or terminate a pregnancy.
Adverse event: Any significant health issue related to the use of abortion drugs, such as fatalities or severe complications.
Gestation: The duration of pregnancy calculated from the last menstrual period.
Health care practitioner: Any licensed individual authorized to prescribe drugs.
Unborn child: An individual organism of the species Homo sapiens from fertilization until birth.

Rule of Construction

The bill clarifies that it does not restrict the authority of the federal government or states to enforce additional regulations regarding abortion drugs.

Relevant Companies

MYR: Potentially affected due to their involvement in the pharmaceutical supply chain for abortion drugs or related healthcare products.

This is an AI-generated summary of the bill text. There may be mistakes.

Actions

2 actions

Date	Action
Jan. 27, 2026	Introduced in Senate
Jan. 27, 2026	Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S292)

Corporate Lobbying

0 companies lobbying

None found.

* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.

Potentially Relevant Congressional Stock Trades

No relevant congressional stock trades found.